As of 05 Nov 2026 18:54 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2025/062 (03 Dec 2025): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Alzest transdermal patches (Dr Reddy’s Laboratories (UK) Ltd) in all strengthsaffected product · inferred from phrasing | Discontinued, as stated | — not stated for this line | update of 08 Jan 2026 |
| Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patchesaffected product · inferred from phrasing | Limited supply, as stated | w/c late September 2026precision: a stated week · window end 06 Oct 2026, derived from “w/c late September 2026” | notice of 03 Dec 2025 |
| Rivastigmine 13.3mg/24hours transdermal patchesnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 03 Dec 2025 |
| Rivastigmine (Zeyzelf) twice weekly 4.6 mg/24hours transdermal patchnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 03 Dec 2025 |
| Rivastigmine (Zeyzelf) twice weekly 9.5 mg/24hours transdermal patchnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 03 Dec 2025 |
| Unlicensed supplies of rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patchesunlicensed import named by the source · inferred from phrasing | Stated as available | — not stated for this line | notice of 03 Dec 2025 |
| Alternative formulations of acetylcholinesterase (AChE) inhibitorsclass-level statement by the source, not a named product · inferred from phrasing | Stated as available⚠ the source line states more than one status — first stated shown | — not stated for this line | notice of 03 Dec 2025 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Rivastigmine 13.3mg/24hours transdermal patches — named by the source as remaining available (inferred from phrasing)
- Rivastigmine (Zeyzelf) twice weekly 4.6 mg/24hours transdermal patch — named by the source as remaining available (inferred from phrasing)
- Rivastigmine (Zeyzelf) twice weekly 9.5 mg/24hours transdermal patch — named by the source as remaining available (inferred from phrasing)
- Unlicensed supplies of rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches — unlicensed import named by the source (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Rivastigmine
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
One supply notification on record, 03 Dec 2025. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 03 Dec 2025 | Medicine Supply Notification: Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches – updated | Notification update | Tier 3 | MSN/2025/062 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2026)18 Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches - Update · issued 12 Jun 2026 · valid until late September 2026, as stated · matched by name PDF ↗
- MSAN(2025)51 Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches · issued 09 Dec 2025 · valid until w/c 22 December 2025, as stated · matched by name PDF ↗